

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	NA

\*FHK- Florida Healthy Kids

## Sublocade (buprenorphine extended-release)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Sublocade (buprenorphine extended-release) subcutaneous injection	May be subject to quantity limit

### APPROVAL CRITERIA

Requests for Sublocade (buprenorphine extended-release) may be approved if the following criteria are met:

- I. The individual has been diagnosed with moderate to severe opioid dependence (opioid use disorder); **AND**
- II. The individual has initiated treatment with buprenorphine (8-24 mg per day) by sublingual tablet or its transmucosal equivalent, followed by dose adjustment for a minimum of 7 days to clinically optimize symptoms of cravings and withdrawal; **AND**
- III. The individual is clinically stable on buprenorphine by sublingual tablet or its transmucosal equivalent prior to initiation of injectable buprenorphine therapy; **AND**
- IV. The individual is not concurrently receiving other maintenance or supplemental dosing with buprenorphine products; **AND**
- V. Injectable buprenorphine is being used as part of a substance use disorder treatment program to include counseling and psychosocial support.

Requests for Sublocade (buprenorphine extended-release) may **not** be approved for to the following criteria:

- I. For individuals with contraindications to injectable buprenorphine, such as a pre-existing severe or moderate hepatic impairment or history of hypersensitivity to buprenorphine; **OR**
- II. For individuals not enrolled in a substance use disorder treatment program to include counseling and psychosocial support.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	NA

\*FHK- Florida Healthy Kids

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

**Key References:**

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: June 14, 2018.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.